Guidance 2022

Cara Therapeutics, Inc. (NASDAQ: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31...

The Analyst Pablo Zuanic, from Cantor Fitzgerald, kept Curaleaf (CSE:CURA) (OTCQX: CURLF) among the firm’s top picks in the MSO group, with an Overweight rating and a price target at US$16.50. The Thesis Curaleaf will report December quarter results on March 3. Zuanic assumes the firm will...